📊 URGN Key Takeaways
Is UroGen Pharma Ltd. (URGN) a Good Investment?
UroGen shows strong product-market traction with 21.4% revenue growth and exceptional 91.9% gross margins, indicating genuine commercial acceptance. However, the company faces severe financial distress: negative stockholders' equity of -$124.3M, operating losses of -$20.3M, and negative free cash flow of -$45.4M represents unsustainable cash burn at ~2.4-year runway against $110M cash reserves. Without dramatic operational leverage or additional financing, the company faces solvency risk.
UroGen Pharma Ltd. Key Strengths (URGN)
- Strong revenue growth of 21.4% YoY demonstrates product commercialization traction
- Exceptional 91.9% gross margin indicates market acceptance and pricing power for core product
- Solid liquidity position with $110M cash and 4.69x current ratio provides near-term operational flexibility
URGN Stock Risks: UroGen Pharma Ltd. Investment Risks
- Negative stockholders' equity of -$124.3M indicates technical insolvency and balance sheet deterioration
- Operating cash flow burn of -$45.3M annually with only ~2.4 years of cash runway at current burn rate
- Operating margin of -39.8% and net margin of -46.3% show inability to achieve operational leverage despite revenue growth
- Total liabilities of $377.9M exceed total assets of $253.7M with $200M long-term debt burden
- Negative operating income of -$20.3M despite $51M revenue suggests severe cost structure misalignment
Key Metrics to Watch
- Operating cash flow trend - must trend positive to validate path to profitability
- Gross margin sustainability - monitor if margin compression occurs with scale
- Operating expense reduction - critical to achieve operating profitability before cash depletes
- Quarterly cash position and burn rate acceleration/deceleration
- Revenue growth maintenance - need continued strong growth to offset cost base
UroGen Pharma Ltd. (URGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.69x current ratio provides a solid financial cushion.
URGN Profit Margin, ROE & Profitability Analysis
URGN vs Healthcare Sector: How UroGen Pharma Ltd. Compares
How UroGen Pharma Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is UroGen Pharma Ltd. Stock Overvalued? URGN Valuation Analysis 2026
Based on fundamental analysis, UroGen Pharma Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
UroGen Pharma Ltd. Balance Sheet: URGN Debt, Cash & Liquidity
URGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: UroGen Pharma Ltd.'s revenue has grown significantly by 129% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.96 indicates the company is currently unprofitable.
URGN Revenue Growth, EPS Growth & YoY Performance
URGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.3M | -$23.6M | $-0.47 |
| Q3 2025 | $25.2M | -$23.7M | $-0.51 |
| Q2 2025 | $21.8M | -$33.4M | $-0.82 |
| Q1 2025 | $18.8M | -$32.3M | $-0.87 |
| Q3 2024 | $20.9M | -$21.9M | $-0.55 |
| Q2 2024 | $21.1M | -$24.1M | $-0.91 |
| Q1 2024 | $17.2M | -$30.2M | $-0.97 |
| Q3 2023 | $16.1M | -$21.9M | $-0.68 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
UroGen Pharma Ltd. Dividends, Buybacks & Capital Allocation
URGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for UroGen Pharma Ltd. (CIK: 0001668243)
📋 Recent SEC Filings
❓ Frequently Asked Questions about URGN
What is the AI rating for URGN?
UroGen Pharma Ltd. (URGN) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are URGN's key strengths?
Claude: Strong revenue growth of 21.4% YoY demonstrates product commercialization traction. Exceptional 91.9% gross margin indicates market acceptance and pricing power for core product.
What are the risks of investing in URGN?
Claude: Negative stockholders' equity of -$124.3M indicates technical insolvency and balance sheet deterioration. Operating cash flow burn of -$45.3M annually with only ~2.4 years of cash runway at current burn rate.
What is URGN's revenue and growth?
UroGen Pharma Ltd. reported revenue of $51.0M.
Does URGN pay dividends?
UroGen Pharma Ltd. does not currently pay dividends.
Where can I find URGN SEC filings?
Official SEC filings for UroGen Pharma Ltd. (CIK: 0001668243) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is URGN's EPS?
UroGen Pharma Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is URGN's fundamental grade?
Based on our AI fundamental analysis in June 2026, UroGen Pharma Ltd. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is URGN stock overvalued or undervalued?
Valuation metrics for URGN: ROE of N/A (sector avg: 15%), net margin of -46.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is URGN's AI grade for 2026?
Our dual AI analysis gives UroGen Pharma Ltd. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is URGN's free cash flow?
UroGen Pharma Ltd.'s operating cash flow is $-45.3M, with capital expenditures of $54.0K. FCF margin is -89.0%.
How does URGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -46.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.69 (avg: 2).